White-Paper-Clinical-Utility-Reimbursement-Molecular-Testing-for-Urinary-Tract-Infection

 

Urinary tract infection (UTI) is the second most common type of infection in the US, accounting for 10.5 million office visits per year and 50 percent of all Medicare hospital admissions. UTI is among the most common cause of bacterial infections in long-term care facility residents.

Effective treatment of a UTI is reliant upon the accurate identification of the pathogens and the correct choice of antibiotics. Although culture-based clinical laboratory testing methods remain the gold standard for diagnosing UTI in both research and clinical laboratories, the clinical utility of such methods continues to be called into question.

 

 

This white paper provides insights on the status of clinical utility of rapid molecular testing for UTI, describes settings where molecular testing for UTI is of high value to improving outcomes, details experiences of successful early adopters of this technology.

Find these, and many more business-critical insights in this White Paper:

  • Learn why a large number of Gram-negative and especially Gram-positive organisms cannot grow in typical culture-based testing conditions, leading to false negatives and missed organisms in a polymicrobial UTI
  • See a comparison study of traditional urine culture testing to multiplex polymerase chain reaction (PCR) molecular testing, run in parallel, showing that the molecular method found six additional polymicrobial cases for every one found using urine cultures
  • How, in addition to higher detection rates, PCR can provide results in as little as 6 hours, and may facilitate more appropriate and efficacious treatment that improves clinical care and outcomes
  • Why insurers and other payers are now acknowledging molecular diagnostic testing, which includes deoxyribonucleic acid-(DNA) or ribonucleic acid-(RNA) based analysis, and much more


White Paper Table of Contents

Chapter 1:
Problems and Limitations of Culture-Based Testing for UTI in Contrast to Molecular Testing

Chapter 2:
Recent Clinical Trials Focused on UTI Diagnostics Using Rapid Molecular Testing

Chapter 3:
Reimbursement Trends and Cost Versus Value in Molecular Testing for UTI

 

CONCLUSION

Molecular tests are becoming more routine as diagnostic tools, with many now covered by Medicare and commercial insurers. Advantages of molecular tests based on PCR technology include their ability to identify uropathogens traditionally missed by culture-based tests.

Driven by urgent, unmet analytical and clinical care needs, the adoption of the rapid molecular test—particularly RT-PCR for urinary tract infection control and treatment—has important implications.

Find out how this innovative testing strategy could benefit your lab by downloading your FREE copy of Molecular Testing for Urinary Tract Infection (UTI)” below.

 

Produced in partnership with:

thermo-fisher-scientific

Download the White Paper now by completing the form below.

Access to some white papers may require registration. In exchange for providing this free content, we may share your information with the companies whose content you choose to view. By accessing the white paper, you’re agreeing to our Terms of Service and Privacy Policy.







Yes! Sign me up for Dark Daily's E-Briefing Service!